{
  "id": "fda_guidance_chunk_0166",
  "title": "Introduction - Part 166",
  "text": "within-subject multi-component endpoints may be efficient if the treatment effects on the different components are generally trending in the same direction within a subject. Study power can be adversely affected, however, if there is limited concordance among the endpoints. Although multi-component endpoints can provide some gains in efficiency compared to coprimary endpoints, the appropriateness of a particular within-subject multi-component endpoint is generally determined by clinical, rather than statistical, considerations. Similar to the assessment of the component endpoints of a composite endpoint in section III.C.3., evaluation of the components of a multi-component endpoint may be important but should be subject to prespecification and multiplicity adjustment if the intent is to support specific conclusions on how a treatment affects specific components (see section III.D.). 11 Contains Nonbinding Recommendations 5. Clinically Critical Endpoints Too Infrequent for Use as a Primary Endpoint For many serious diseases, there is an endpoint of such great clinical importance that it is unreasonable not to collect and analyze the endpoint data; the usual example is mortality or major morbidity events (e.g., stroke, fracture, pulmonary exacerbation). Even if relatively few of these events are expected to occur in the trial, they can be included in a composite endpoint (see section III.C.3.) and also designated as a planned secondary endpoint to potentially support a conclusion regarding effect on that separate endpoint, if the effect of the drug on the composite primary endpoint is demonstrated. D. 1. The Individual Components of Composite and Multi-Component Endpoints Evaluating and Reporting the Results of Composite Endpoints For composite endpoints whose components correspond to events, an event is usually defined as the first occurrence of any of the designated component events. Such composites can be analyzed either with comparisons of proportions between study groups at the end of the study or using time-to-event analyses. The time-to-event method of analysis is the more common method when, within the studyâ€™s timeframe of observation, the duration of being event-free is clinically meaningful. Although there may be an expectation that the drug will have a favorable effect on all the components of a composite endpoint, that is not a certainty. Results for each component event should therefore be individually examined and should be included in study reports. These analyses will not alter a conclusion about the statistical significance of the composite primary endpoint;",
  "source": "FDA_clinical_trial_guidance.txt",
  "section_heading": "Introduction",
  "start_pos": 221760,
  "end_pos": 223296,
  "tokens": 512,
  "tags": [
    "safety",
    "efficacy",
    "statistical",
    "clinical_trial",
    "data"
  ],
  "jurisdiction": "US",
  "document_type": "fda_guidance",
  "guidance_section": "general_guidance",
  "regulatory_weight": "recommendation",
  "created_at": "2025-10-23T02:25:44.688Z"
}